Sustained-release composition including amorphous polymer
OwnerTheodore W. Randolph, Mark C. Manning +1inventors
InventorsTheodore W. Randolph, Mark C. Manning, Richard F. Falk
Life of this patent
Estimating the term…
Abstract
Provided is a sustained release composition for sustained release of a pharmaceutical substance. The composition includes a biocompatible polymer that is highly amorphous and a pharmaceutical substance in a hydrophobic ion complex with an amphiphilic material. Also provided is a compressed antisolvent method for manufacturing the composition, various product forms incorporating the composition and various uses for the composition.
Claims48
A method for producing a biocompatible polymer particle for sustained release of a pharmaceutical substance, wherein said particle comprises substantially amorphous biocompatible polymer having a crystallinity of no more than about 25%, and wherein said particle comprises a substantially homogeneous mixture of said pharmaceutical substance and said amorphous polymer;
- comprising the steps of:
- a) providing:
- i) a solvent,
- ii) a pharmaceutical substance,
- iii) an amphiphilic material, selected from the group consisting of sulfates, sulfonates, phosphates, phospholipids, carboxylates, sulfosuccinates, arginine esters, cholesterol esters, carbamates, carbonates and ketals,
- iv) at least one biocompatible polymer selected from the group consisting of poly(L-lactic) acid, poly(D-lactic) acid, polyglycolic acid, polyanhydride, polycarboxyphenoxyhexane, polybutyrate, and cellulose;
- and
- v) an antisolvent fluid, wherein said antisolvent fluid comprises at least one antisolvent selected from the group consisting of carbon dioxide, nitrous oxide, ethane ethylene, chlorotrifluoromethane, monofluoromethane, acetylene, 1,1-difluoroethylene, hexafluoroethane, chlorotrifluorosilane and xenon;
- b) combining said solvent, pharmaceutical substance and amphiphilic material to form a solution, wherein said pharmaceutical substance and amphiphilic material form a hydrophobic ion paired complex within said solution;
- and
- c) contacting at subcritical conditions said solution, said polymer, and said antisolvent fluid by concurrent flow to produce a mixture, wherein said mixture has a reduced temperature in the range of about 0.75-0.995, and wherein a reduced pressure relative to the antisolvent fluid is in the range of about 0.5-2.0, wherein the weight percentage of said hydrophobic ion paired complex to the total weight of said hydrophobic ion paired complex and said polymer is in the range of about 15% to 70%, and wherein the volumetric ratio of flow rate of said antisolvent fluid to the flow rate of said solution is in the range from about 5 to about 100.
A biocompatible polymer particle for sustained release of a pharmaceutical substance, wherein said particle comprises a substantially amorphous biocompatible polymer having a crystallinity of no more than about 25%, wherein said pharmaceutical substance is combined with an amphiphilic material to form a hydrophobic ion paired complex;
- wherein said biocompatible polymer comprises at least one polymer selected from the group consisting of poly(L-lactic) acid, poly(D-lactic) acid, polyglycolic acid, polyanhydride, polycarboxyphenoxyhexane, polybutyrate, and cellulose;
- wherein said amphiphilic material is selected from the group consisting of sodium dodecyl sulfate, bis-(2-ethylhexyl) sodium sulfosuccinate, cholesterol sulfate and sodium laurate;
- wherein said particle comprises a substantially homogeneous mixture of said pharmaceutical substance and said amorphous biocompatible polymer;
- wherein the weight percentage of said hydrophobic ion paired complex to the total weight of said hydrophobic ion paired complex and said biocompatible polymer is in the range of about 15% to 70%.
Dependencies are inferred from the claim text.